Academic Journal
The Combined Effects of RhBMP-2 and Systemic RANKL Inhibitor in Patients With Bone Density Loss Undergoing Posterior Lumbar Interbody Fusion: A Retrospective Observational Analysis With Propensity Score Matching
| العنوان: | The Combined Effects of RhBMP-2 and Systemic RANKL Inhibitor in Patients With Bone Density Loss Undergoing Posterior Lumbar Interbody Fusion: A Retrospective Observational Analysis With Propensity Score Matching |
|---|---|
| المؤلفون: | Seungjun Ryu, Seon-Jin Yoon, Chang Kyu Lee, Seong Yi, Keung-Nyun Kim, Yoon Ha, Dong Ah Shin |
| المصدر: | Neurospine, Vol 20, Iss 4, Pp 1186-1192 (2023) |
| بيانات النشر: | Korean Spinal Neurosurgery Society, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neurology. Diseases of the nervous system |
| مصطلحات موضوعية: | posterior lumbar interbody fusion, osteoporosis, osteopenia, bone morphogenic protein 2, Neurology. Diseases of the nervous system, RC346-429 |
| الوصف: | Objective The risks of nonunion and subsidence are high in patients with bone density loss undergoing spinal fusion surgery. The internal application of recombinant human bone morphogenic protein 2 (rhBMP-2) in an interbody cage improves spinal fusion; however, related complications have been reported. Denosumab, a human monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand (RANKL), hinders osteoblast differentiation and function. Therefore, this study aimed to observe the combined effect of the local application of rhBMP-2 in a lumbar cage and systemic RANKL inhibition on postoperative spinal fusion in patients with bone density loss undergoing posterior lumbar interbody fusion (PLIF). Methods This retrospective observational study included 251 consecutive patients with spinal stenosis who underwent PLIF at a single center between 2017 and 2021. Clinical outcomes were assessed, and radiographic evaluations included lumbar flexion, extension, range of motion, and subsidence. Statistical analyses were conducted to identify the combined effect of the treatment and the subsidence and spinal fusion status. Results One hundred patients were included in the final analysis. Denosumab treatment significantly reduced the rate of osteolysis (p = 0.013). When denosumab was administered in combination with rhBMP-2, the fusion status remained similar; however, the incidences of postoperative osteolysis and postoperative oozing day decreased. Conclusion The combined use of rhBMP-2 and RANKL inhibition in patients with bone density loss can enhance bone formation after PLIF with fewer complications than rhBMP-2 alone. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2586-6583 2586-6591 |
| Relation: | http://e-neurospine.org/upload/pdf/ns-2346702-351.pdf; https://doaj.org/toc/2586-6583; https://doaj.org/toc/2586-6591 |
| DOI: | 10.14245/ns.2346702.351 |
| URL الوصول: | https://doaj.org/article/bb80364f2c204e198748625e613e8e35 |
| رقم الانضمام: | edsdoj.bb80364f2c204e198748625e613e8e35 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 25866583 25866591 |
|---|---|
| DOI: | 10.14245/ns.2346702.351 |